Las acciones de DataMeds AI (MEDS) se desploman un 11% a pesar del debut de la app de salud con GLP-1

Blockonomi · 2026-09-28T12:24:27.000Z

Puntos clave DataMeds AI se asoció con Tollo Health para presentar el lanzamiento de la plataforma móvil Health Lives Here para personas que usan medicamentos con GLP-1. La plataforma llega a los consumidores a través de una colaboración con NFL Alumni Health. Una red inicial de farmacias se lanza con Moose Pharmacy de Concord, con sede en Carolina del Norte. Las acciones de MEDS cayeron un 11% tras el anuncio. La expansión futura se dirige a personas que sufren de Long COVID y pacientes con cáncer en 2026 y en adelante. Las acciones de DataMeds AI (MEDS) cayeron un 11% el lunes tras el anuncio de la nueva aplicación de salud. La acción cerró en $3.11 durante el horario de operaciones.

Key Takeaways
DataMeds AI partnered with Tollo Health to debut the Health Lives Here mobile platform for individuals using GLP-1 medications.
The platform reaches consumers through a collaboration with NFL Alumni Health.
An initial pharmacy network launches with Moose Pharmacy of Concord based in North Carolina.
MEDS shares declined 11% following the announcement.
Future expansion targets Long COVID sufferers and cancer patients in 2026 and beyond.
Shares of DataMeds AI (MEDS) tumbled 11% Monday following the new health app announcement. The stock settled at $3.11 during trading hours.
The Florida-headquartered firm collaborated with Tollo Health to introduce the Health Lives Here mobile platform. The application’s initial focus centers on individuals taking GLP-1 receptor agonist drugs.
Distribution of the platform leverages a collaboration with NFL Alumni Health, the wellness division of the National Football League Alumni Association.
New Healthcare Network Debuts With Pharmacy Partner
Accompanying the release is a newly established Health Lives Here healthcare network. The network begins with select independent pharmacies curated from Corexa Health subsidiary’s current pharmacy roster.
Moose Pharmacy of Concord in North Carolina serves as the inaugural network participant. Additional pharmacy locations will be added progressively.
The platform facilitates connections between users and credentialed physicians for virtual medical consultations. Patients can undergo GLP-1 therapy evaluations directly through their mobile devices.
Through Corexa’s pharmacy division, patients access cash-payment alternatives for brand-name GLP-1 medications. Direct-to-home shipping is available, with the option to transfer prescriptions to any preferred local pharmacy.
The application additionally markets Tollo Health’s Forzet, a medical food formulation. The product aims to address muscle degradation associated with weight reduction therapies and requires no prescription.
Platform Integrates Wearable Technology and AI Tools
Health Lives Here syncs with leading wearable devices. Compatible products include Apple Watch, Samsung Galaxy Watch, WHOOP, and Oura Ring.
An AI-powered health coaching system and activity tracking features come standard with the platform. A specialized AI chatbot monitors for crisis-related communication and directs users to urgent assistance resources.
DataMeds AI has broader ambitions beyond GLP-1 medication users. The firm intends to extend platform access to Long COVID patients during Q4 2026.
Oncology patients represent the subsequent expansion target. The company hasn’t specified exact dates for this rollout phase.
Laboratory diagnostic services are under development. These offerings would leverage the Helomics Corporation acquisition, enabling consumers to purchase lab testing directly in jurisdictions that permit it.
Long-term objectives include incorporating digital twin technology. An expanded provider network is scheduled for 2027.
Gerald Commissiong holds the position of Interim Co-CEO at DataMeds AI. He simultaneously leads Tollo Health as CEO, the company behind the platform partnership.
The significant stock decline contrasts sharply with the product announcement. Market participants may be evaluating implementation challenges relative to the nascent stage of the platform release.
Currently, the Health Lives Here platform operates with a single pharmacy collaborator. While the company has outlined an ambitious multi-year strategy, no user adoption metrics or revenue projections have been disclosed for the launch.
The post DataMeds AI (MEDS) Stock Plunges 11% Despite GLP-1 Health App Debut appeared first on Blockonomi.